Isofol Medical AB (publ) appoints Jenny Sundqvist as Chief Commercial Officer

GOTHENBURG, Sweden, December 10, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced the appointment of Jenny Sundqvist as Chief Commercial Officer (CCO) as of January 1, 2022. Jenny is currently the Head of Commercial and Strategy Development at Isofol. Former CCO, Tony Gustavsson, leaves Isofol for a new international assignment in a global pharmaceutical group.

In her new role as CCO, Jenny Sundqvist will be part of Isofol’s senior management team and will be responsible for implementing the commercial preparations that were intensified in 2021. During the year, Isofol strengthened its commercial resources internally in the company as well as engaged additional external resources with the ambition that market approval of arfolitixorin will be possible during the second half of 2023, given a positive outcome from the ongoing phase III study.

– To create the best possible conditions for the commercial launch, Isofol has already initiated several measures within the framework of our global preparation program. With Jenny at the helm, I am convinced that we will continue these efforts at the same pace in the future as well. At the same time, I would like to take this opportunity to thank Tony for his valuable efforts on behalf of Isofol and wish him the best of luck with his new prestigious assignment, says Ulf Jungnelius, CEO of Isofol.

– I look forward to taking on the CCO role and it is an honor to be responsible for the commercial preparations so that a new treatment alternative for advanced colorectal cancer may be offered to patients with this difficult disease. We have made significant progress with our commercial preparations and strengthened our collaboration with external partners to create the best possible conditions, says Jenny Sundqvist, incoming CCO at Isofol.

Jenny Sundqvist joined Isofol in August 2021 after serving as AstraZeneca’s Head of Oncology Portfolio accountable for the yearly oncology strategy. At AstraZeneca, she was also Site Director of one of the company’s three R&D sites. Jenny has a strong commercial and strategic background including roles such Management Consultant, Head of Marketing, PR, and Product Development within pharmaceutical, medical device and consumers goods. Jenny holds a Bachelor of Science degree in international trade and finance and an MBA.

For further information, please contact

Isofol Medical AB (publ)
Jarl Ulf Jungnelius, M.D., Chief Executive Officer
E-mail: jungnelius@isofolmedical.com
Phone: +46 (0) 709 16 89 55

The information was submitted for publication, through the agency of the contact person set out above, at 16:30 CET on December 10, 2021.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB (publ) is traded on the Nasdaq Stockholm.

www.isofolmedical.com

Document